Kalden JR - Search Results

1

Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.

Valerius T, Repp R, de Wit TP, Berthold S, Platzer E, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Among authors: kalden jr. Blood. 1993 Aug 1;82(3):931-9. Blood. 1993. PMID: 7687898 Free article.

2

Human granulocyte colony stimulating factor: effects on human long-term bone marrow cultures.

Platzer E, Simon S, Kalden JR. Platzer E, et al. Among authors: kalden jr. Blood Cells. 1988;14(2-3):463-9. Blood Cells. 1988. PMID: 2465793

3

HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.

Elsässer D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, van de Winkel JG, Stevenson GT, Glennie MJ, Gramatzki M. Elsässer D, et al. Among authors: kalden jr. Blood. 1996 May 1;87(9):3803-12. Blood. 1996. PMID: 8611706 Free article.

4

Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.

Stockmeyer B, Valerius T, Repp R, Heijnen IA, Bühring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JG. Stockmeyer B, et al. Among authors: kalden jr. Cancer Res. 1997 Feb 15;57(4):696-701. Cancer Res. 1997. PMID: 9044847

5

Clinical relevance of Fc gamma receptor polymorphisms.

Rascu A, Repp R, Westerdaal NA, Kalden JR, van de Winkel JG. Rascu A, et al. Among authors: kalden jr. Ann N Y Acad Sci. 1997 Apr 5;815:282-95. doi: 10.1111/j.1749-6632.1997.tb52070.x. Ann N Y Acad Sci. 1997. PMID: 9186665 Review.

6

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.

Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Among authors: kalden jr. Blood. 1997 Dec 1;90(11):4485-92. Blood. 1997. PMID: 9373259 Free article.

7

Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

Würflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M, Gramatzki M. Würflein D, et al. Among authors: kalden jr. Cancer Res. 1998 Jul 15;58(14):3051-8. Cancer Res. 1998. PMID: 9679970

8

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T. Stockmeyer B, et al. Among authors: kalden jr. J Immunol. 2000 Nov 15;165(10):5954-61. doi: 10.4049/jimmunol.165.10.5954. J Immunol. 2000. PMID: 11067958

9

Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?

Stadick H, Stockmeyer B, Kühn R, Schrott KM, Kalden JR, Glennie MJ, van de Winkel JG, Gramatzki M, Valerius T, Elsässer D. Stadick H, et al. Among authors: kalden jr. J Urol. 2002 Feb;167(2 Pt 1):707-12. doi: 10.1016/S0022-5347(01)69131-6. J Urol. 2002. PMID: 11792958

10

Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E. Repp R, et al. Among authors: kalden jr. Blood. 1991 Aug 15;78(4):885-9. Blood. 1991. PMID: 1714327 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

616 results

Search Page

Filters